ATYR
Price
$2.75
Change
-$0.12 (-4.18%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
243.47M
26 days until earnings call
DMAC
Price
$3.50
Change
-$0.21 (-5.68%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
150.42M
39 days until earnings call
Ad is loading...

ATYR vs DMAC

Header iconATYR vs DMAC Comparison
Open Charts ATYR vs DMACBanner chart's image
aTyr Pharma
Price$2.75
Change-$0.12 (-4.18%)
Volume$15.28K
Capitalization243.47M
DiaMedica Therapeutics
Price$3.50
Change-$0.21 (-5.68%)
Volume$707
Capitalization150.42M
ATYR vs DMAC Comparison Chart
Loading...
ATYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATYR vs. DMAC commentary
Apr 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATYR is a Hold and DMAC is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 11, 2025
Stock price -- (ATYR: $2.74 vs. DMAC: $3.51)
Brand notoriety: ATYR and DMAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATYR: 81% vs. DMAC: 63%
Market capitalization -- ATYR: $243.47M vs. DMAC: $150.42M
ATYR [@Biotechnology] is valued at $243.47M. DMAC’s [@Biotechnology] market capitalization is $150.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $263.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATYR’s FA Score shows that 0 FA rating(s) are green whileDMAC’s FA Score has 0 green FA rating(s).

  • ATYR’s FA Score: 0 green, 5 red.
  • DMAC’s FA Score: 0 green, 5 red.
According to our system of comparison, ATYR is a better buy in the long-term than DMAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATYR’s TA Score shows that 3 TA indicator(s) are bullish while DMAC’s TA Score has 4 bullish TA indicator(s).

  • ATYR’s TA Score: 3 bullish, 5 bearish.
  • DMAC’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, DMAC is a better buy in the short-term than ATYR.

Price Growth

ATYR (@Biotechnology) experienced а -1.79% price change this week, while DMAC (@Biotechnology) price change was -4.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.33%. For the same industry, the average monthly price growth was -17.76%, and the average quarterly price growth was -19.66%.

Reported Earning Dates

ATYR is expected to report earnings on May 07, 2025.

DMAC is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (-7.33% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATYR($243M) has a higher market cap than DMAC($150M). ATYR YTD gains are higher at: -20.994 vs. DMAC (-31.308). DMAC has higher annual earnings (EBITDA): -24.07M vs. ATYR (-66.37M). ATYR has more cash in the bank: 72.1M vs. DMAC (50.2M). DMAC has less debt than ATYR: DMAC (365K) vs ATYR (13.3M). ATYR has higher revenues than DMAC: ATYR (235K) vs DMAC (0).
ATYRDMACATYR / DMAC
Capitalization243M150M162%
EBITDA-66.37M-24.07M276%
Gain YTD-20.994-31.30867%
P/E RatioN/AN/A-
Revenue235K0-
Total Cash72.1M50.2M144%
Total Debt13.3M365K3,644%
FUNDAMENTALS RATINGS
ATYR vs DMAC: Fundamental Ratings
ATYR
DMAC
OUTLOOK RATING
1..100
5956
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
64
Fair valued
PROFIT vs RISK RATING
1..100
9190
SMR RATING
1..100
9594
PRICE GROWTH RATING
1..100
5565
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DMAC's Valuation (64) in the Biotechnology industry is in the same range as ATYR (82) in the null industry. This means that DMAC’s stock grew similarly to ATYR’s over the last 12 months.

DMAC's Profit vs Risk Rating (90) in the Biotechnology industry is in the same range as ATYR (91) in the null industry. This means that DMAC’s stock grew similarly to ATYR’s over the last 12 months.

DMAC's SMR Rating (94) in the Biotechnology industry is in the same range as ATYR (95) in the null industry. This means that DMAC’s stock grew similarly to ATYR’s over the last 12 months.

ATYR's Price Growth Rating (55) in the null industry is in the same range as DMAC (65) in the Biotechnology industry. This means that ATYR’s stock grew similarly to DMAC’s over the last 12 months.

ATYR's P/E Growth Rating (100) in the null industry is in the same range as DMAC (100) in the Biotechnology industry. This means that ATYR’s stock grew similarly to DMAC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATYRDMAC
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 29 days ago
80%
Bullish Trend 25 days ago
84%
Declines
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 3 days ago
82%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
77%
View a ticker or compare two or three
Ad is loading...
ATYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CMVIX20.30N/A
N/A
BlackRock Advantage Large Cap Gr Instl
AZNIX10.75N/A
N/A
Virtus Income & Growth Inst
TEOJX7.52N/A
N/A
Transamerica Emerging Markets Eq I2
GEICX6.41N/A
N/A
Gabelli Equity Income C
LRAGX12.54N/A
N/A
Lord Abbett International Growth R3

ATYR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATYR has been loosely correlated with MGTX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ATYR jumps, then MGTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATYR
1D Price
Change %
ATYR100%
+5.15%
MGTX - ATYR
44%
Loosely correlated
+2.39%
NTLA - ATYR
36%
Loosely correlated
+12.74%
SLDB - ATYR
35%
Loosely correlated
+2.62%
AMLX - ATYR
35%
Loosely correlated
+5.59%
CRNX - ATYR
35%
Loosely correlated
+8.18%
More

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with WHWK. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+10.36%
WHWK - DMAC
43%
Loosely correlated
+4.43%
VTGN - DMAC
28%
Poorly correlated
+2.46%
ATYR - DMAC
28%
Poorly correlated
+5.15%
DSGN - DMAC
27%
Poorly correlated
+0.51%
AVXL - DMAC
26%
Poorly correlated
+14.61%
More